Literature DB >> 14734187

Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP.

Marcelo L Ribeiro1, Monique M Gerrits, Yune H B Benvengo, Marco Berning, Anita P O Godoy, Ernst J Kuipers, Sergio Mendonça, Arnoud H M van Vliet, José Pedrazzoli, Johannes G Kusters.   

Abstract

Tetracycline is one of four antibiotics commonly used for the treatment of Helicobacter pylori infection, but its effectiveness is decreasing as the incidence of tetracycline resistance is increasing. In five Brazilian tetracycline-resistant (Tet(R)) H. pylori isolates, high-level tetracycline resistance is mediated by the triple-base-pair substitution AGA(926-928)-->TTC in both 16S rRNA genes, as was previously observed in two independent high-level Tet(R) H. pylori strains. A polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) assay was developed for the detection of the AGA(926-928)-->TTC substitution, and confirmed the presence of the aforementioned triple-base-pair substitution in all five Brazilian Tet(R) isolates. This PCR-RFLP-based approach distinguishes the high-level Tet(R) isolates from low-level Tet(R) and Tet(S) H. pylori strains and thus allows the direct detection of Tet(R) H. pylori isolates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734187     DOI: 10.1016/S0928-8244(03)00277-3

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  15 in total

1.  Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori.

Authors:  Erik Glocker; Marco Berning; Monique M Gerrits; Johannes G Kusters; Manfred Kist
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Evaluation of seaFAST, a rapid fluorescent in situ hybridization test, for detection of Helicobacter pylori and resistance to clarithromycin in paraffin-embedded biopsy sections.

Authors:  Julie M Morris; Alisa L Reasonover; Michael G Bruce; Dana L Bruden; Brian J McMahon; Frank D Sacco; Douglas E Berg; Alan J Parkinson
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

3.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

4.  16S rRNA mutations that confer tetracycline resistance in Helicobacter pylori decrease drug binding in Escherichia coli ribosomes.

Authors:  Lisa Nonaka; Sean R Connell; Diane E Taylor
Journal:  J Bacteriol       Date:  2005-06       Impact factor: 3.490

Review 5.  Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.

Authors:  Francis Mégraud
Journal:  Gut Microbes       Date:  2013-08-05

Review 6.  Helicobacter pylori detection and antimicrobial susceptibility testing.

Authors:  Francis Mégraud; Philippe Lehours
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

Review 7.  Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions.

Authors:  Aleksandra Sokic-Milutinovic; Tamara Alempijevic; Tomica Milosavljevic
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 8.  Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.

Authors:  Evariste Tshibangu-Kabamba; Yoshio Yamaoka
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-17       Impact factor: 46.802

9.  Absence of Helicobacter pylori high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil.

Authors:  Rodrigo Buzinaro Suzuki; Cristiane Maria Almeida; Márcia Aparecida Sperança
Journal:  BMC Gastroenterol       Date:  2012-05-17       Impact factor: 3.067

10.  Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication.

Authors:  Wenming Wu; Yunsheng Yang; Gang Sun
Journal:  Gastroenterol Res Pract       Date:  2012-07-05       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.